Citadel Advisors
SLS icon

Citadel Advisors’s SELLAS Life Sciences SLS Stock Holding History

Citadel Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.5M Buy
4,368,200
+2,474,600
+131% +$11.1M ﹤0.01% 2419
2025
Q4 		$7.14M Buy
1,893,600
+1,360,500
+255% +$2.64M ﹤0.01% 3732
2025
Q3 		$858K Buy
533,100
+73,200
+16% +$130K ﹤0.01% 7877
2025
Q2 		$1.01M Buy
459,900
+195,300
+74% +$300K ﹤0.01% 7065
2025
Q1 		$286K Buy
264,600
+38,200
+17% +$45.3K ﹤0.01% 9713
2024
Q4 		$235K Buy
226,400
+63,600
+39% +$72.6K ﹤0.01% 10141
2024
Q3 		$204K Buy
162,800
+14,600
+10% +$17.8K ﹤0.01% 10119
2024
Q2 		$176K Buy
148,200
+800
+0.5% +$1.09K ﹤0.01% 10113
2024
Q1 		$149K Sell
147,400
-118,600
-45% -$99.6K ﹤0.01% 10772
2023
Q4 		$282K Buy
266,000
+11,100
+4% +$12K ﹤0.01% 9297
2023
Q3 		$418K Sell
254,900
-19,800
-7% -$31.2K ﹤0.01% 8468
2023
Q2 		$431K Buy
274,700
+12,100
+5% +$19.4K ﹤0.01% 8261
2023
Q1 		$376K Sell
262,600
-67,800
-21% -$168K ﹤0.01% 8904
2022
Q4 		$780K Sell
330,400
-47,600
-13% -$134K ﹤0.01% 7312
2022
Q3 		$764K Sell
378,000
-25,900
-6% -$71.5K ﹤0.01% 7575
2022
Q2 		$901K Buy
403,900
+245,300
+155% +$719K ﹤0.01% 7256
2022
Q1 		$1.06M Sell
158,600
-108,700
-41% -$636K ﹤0.01% 7553
2021
Q4 		$1.48M Buy
267,300
+227,000
+563% +$1.72M ﹤0.01% 6919
2021
Q3 		$369K Sell
40,300
-41,700
-51% -$387K ﹤0.01% 10590
2021
Q2 		$910K Buy
82,000
+39,200
+92% +$383K ﹤0.01% 8601
2021
Q1 		$366K Buy
42,800
+18,400
+75% +$151K ﹤0.01% 10386
2020
Q4 		$142K Buy
+24,400
New +$97.7K ﹤0.01% 9987
2018
Q1 		– Sell
-8
Closed -$3K – 8732
2017
Q4 		$3K Buy
+8
New +$3.87K ﹤0.01% 7909

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's SLS Position: Q1 2026 in Review

Citadel Advisors opened a new position in SELLAS Life Sciences (SLS) in Q1 2026: 64,641 shares worth $273K. The stake represents ﹤0.01% of the portfolio and ranks #10681 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SLS as recently as Q3 2025.

Citadel Advisors first reported a position in SLS in Q4 2016 and has held it in 24 quarters since. The position peaked at $505K in Q4 2024. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Citadel Advisors held 64,641 shares of SELLAS Life Sciences worth $273K as of Q1 2026.
  • SELLAS Life Sciences was a new Citadel Advisors position in Q1 2026.
  • SELLAS Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10681 holding.
  • Citadel Advisors first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 24 quarters since.
  • Citadel Advisors's SELLAS Life Sciences position peaked at $505K in Q4 2024.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.